443 related articles for article (PubMed ID: 18181236)
1. 6alpha-Methylandrostenedione: gas chromatographic mass spectrometric detection in doping control.
Parr MK; Kazlauskas R; Schlörer N; Opfermann G; Piper T; Schulze G; Schänzer W
Rapid Commun Mass Spectrom; 2008; 22(3):321-9. PubMed ID: 18181236
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control.
Parr MK; Fusshöller G; Schlörer N; Opfermann G; Piper T; Rodchenkov G; Schänzer W
Rapid Commun Mass Spectrom; 2009 Jan; 23(2):207-18. PubMed ID: 19089863
[TBL] [Abstract][Full Text] [Related]
3. Alternative long-term markers for the detection of methyltestosterone misuse.
Gómez C; Pozo OJ; Marcos J; Segura J; Ventura R
Steroids; 2013 Jan; 78(1):44-52. PubMed ID: 23127819
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of methyltestosterone in the greyhound.
Biddle ST; O'Donnell A; Houghton E; Creaser C
Rapid Commun Mass Spectrom; 2009 Mar; 23(5):713-21. PubMed ID: 19199316
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.
Kohler M; Parr MK; Opfermann G; Thevis M; Schlörer N; Marner FJ; Schänzer W
Steroids; 2007 Mar; 72(3):278-86. PubMed ID: 17207827
[TBL] [Abstract][Full Text] [Related]
6. Detection of androst-4-ene-3,6,17-trione (6-OXO) and its metabolites in urine by gas chromatography-mass spectrometry in relation to doping analysis.
Van Thuyne W; Van Eenoo P; Mikulcíková P; Deventer K; Delbeke FT
Biomed Chromatogr; 2005 Nov; 19(9):689-95. PubMed ID: 15828056
[TBL] [Abstract][Full Text] [Related]
7. Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".
Cawley AT; Hine ER; Trout GJ; George AV; Kazlauskas R
Forensic Sci Int; 2004 Jul; 143(2-3):103-14. PubMed ID: 15240029
[TBL] [Abstract][Full Text] [Related]
8. Urinary metabolic profile of 19-norsteroids in humans: glucuronide and sulphate conjugates after oral administration of 19-nor-4-androstenediol.
Torrado S; Roig M; Farré M; Segura J; Ventura R
Rapid Commun Mass Spectrom; 2008 Oct; 22(19):3035-42. PubMed ID: 18763272
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the steroid profile in doping control analysis.
Mareck U; Geyer H; Opfermann G; Thevis M; Schänzer W
J Mass Spectrom; 2008 Jul; 43(7):877-91. PubMed ID: 18570179
[TBL] [Abstract][Full Text] [Related]
10. Detection of Δ6-methyltestosterone in a "dietary supplement" and GC-MS/MS investigations on its urinary metabolism.
Parr MK; Fusshöller G; Schlörer N; Opfermann G; Geyer H; Rodchenkov G; Schänzer W
Toxicol Lett; 2011 Mar; 201(2):101-4. PubMed ID: 21134425
[TBL] [Abstract][Full Text] [Related]
11. Urine stability and steroid profile: towards a screening index of urine sample degradation for anti-doping purpose.
Mazzarino M; Abate MG; Alocci R; Rossi F; Stinchelli R; Molaioni F; de la Torre X; Botrè F
Anal Chim Acta; 2011 Jan; 683(2):221-6. PubMed ID: 21167974
[TBL] [Abstract][Full Text] [Related]
12. Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing.
Piper T; Emery C; Thomas A; Saugy M; Thevis M
Anal Bioanal Chem; 2013 Jun; 405(16):5455-66. PubMed ID: 23568614
[TBL] [Abstract][Full Text] [Related]
13. Metabolic studies of mesterolone in horses.
Ho EN; Leung DK; Leung GN; Wan TS; Wong HN; Xu X; Yeung JH
Anal Chim Acta; 2007 Jul; 596(1):149-55. PubMed ID: 17616252
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of androst-4-ene-3,6,17-trione and metabolites in human urine after the administration of a food supplement by liquid chromatography/ion trap-mass spectrometry.
Deventer K; Van Eenoo P; Mikulcíková P; Van Thuyne W; Delbeke FT
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Dec; 828(1-2):21-6. PubMed ID: 16213800
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS.
Fragkaki AG; Angelis YS; Kiousi P; Georgakopoulos CG; Lyris E
J Mass Spectrom; 2015 May; 50(5):740-8. PubMed ID: 26259657
[TBL] [Abstract][Full Text] [Related]
16. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
17. Alternative markers for Methylnortestosterone misuse in human urine.
Sakellariou P; Kiousi P; Fragkaki AG; Lyris E; Petrou M; Georgakopoulos C; Angelis YS
Drug Test Anal; 2020 Nov; 12(11-12):1544-1553. PubMed ID: 32602999
[TBL] [Abstract][Full Text] [Related]
18. Determination of the deuterium/hydrogen ratio of endogenous urinary steroids for doping control purposes.
Piper T; Thevis M; Flenker U; Schänzer W
Rapid Commun Mass Spectrom; 2009 Jul; 23(13):1917-26. PubMed ID: 19462405
[TBL] [Abstract][Full Text] [Related]
19. Determination of Xipamide metabolite in human urine by high-performance liquid chromatography/diode-array detection, high-performance liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry.
Kim Y; Han K; Paeng KJ
Rapid Commun Mass Spectrom; 2004; 18(20):2505-12. PubMed ID: 15384135
[No Abstract] [Full Text] [Related]
20. Addressing recent challenges in isotope ratio mass spectrometry: Development of a method applicable to 1-androstene-steroids, 6α-hydroxy-androstenedione, and androstatrienedione.
Piper T; Thevis M
Drug Test Anal; 2022 Nov; 14(11-12):1891-1903. PubMed ID: 36001066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
